Zai Lab Limited
Basic information
- Head office
- Building B, 899 Halei Road Pudong, 201203 China
- Chief executive
- Ying Du
- Employees (non-consolidated)
- 1,784 people
- Employees (consolidated)
- Start date
- 2013-01-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
| GE Healthcare | ||||||||
| MediLink Therapeutics | ||||||||
| innovaTV |
Network
History
In the second quarter of 2017, Zai Lab initiated a Phase II trial of ZL-2301 as a second-line treatment for advanced hepatocellular cancer patients in China.
Zai Lab initiated a Phase II study of ZL-3101 in eczema patients in China during the second quarter of 2017.
In April 2017, Zai Lab in-licensed exclusive regional rights to ZL-2401, a broad spectrum antibiotic, from Paratek Pharmaceuticals.
In September 2017, Zai Lab dosed the first patient in its Phase 3 China registration trial of ZL-2306 as a second-line maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.
In November 2017, Zai Lab initiated a pharmacokinetic (PK) study to establish the PK profile of ZL-2306 in Chinese patients.
In December 2017, Zai Lab in-licensed exclusive regional rights to FPA 144 from Five Prime Therapeutics.
In the US, an NDA was submitted for ZL-2401 in February 2018.
Zai Lab entered in to an exclusive licensing agreement and collaboration with Entasis Therapeutics for ETX2514 on April 25, 2018.
On August 8, 2018, Antimicrobials Drug Advisory Committee of the U.S. FDA voted in favor of the approval of IV and oral omadacycline.
News
There is no news.